$MSFT
- Satya Nadella has made Microsoft 10 times more valuable in his decade as CEO. Can he stay ahead in the AI age? fortune.com/2024/05/20/sat…

$ARGX $ALNY $VKTX $ITCI $RVMD $BPMC $CYTK $BBIO $APLS $MDGL $IBRX $CRSP $KRYS $IMVT $AXSM $BHVN $ARWR $IDYA $XENE $IOVA $FOLD $RNA $IMCR $TGTX $NTLA $MLTX $RYTM $ARVN $ARDX $VRNA. - Wells Fargo Names Potential M&A Targets seekingalpha.com/news/4110471-v…

$INBX $SNY
- Inhibrx Stockholders Approve Sale of INBRX-101 to Sanofi prn.to/3yJATeL

$SCNI
- Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity Listing Requirements & Hearing to Present a Plan for Regaining Compliance
prn.to/4bzdGdQ

$NA
Nano Labs Announces Receipt of Deficiency Letters from Nasdaq prn.to/3VdUrkh

$RXRX
- Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board globenewswire.com/news-release/2…

$IDEX
- Ideanomics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q globenewswire.com/news-release/2…

$BRTX
- BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice globenewswire.com/news-release/2…

$NVS
- Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo globenewswire.com/news-release/2…

$NVS
- Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio globenewswire.com/news-release/2…

$VERA
- Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress globenewswire.com/news-release/2…

$RKLB
- Rocket Lab Successfully Launches First of Two Climate Science Satellites for NASA - businesswire.com/news/home/2024…

$GH
- FDA advisers endorse Guardant Health’s colon cancer screening test statnews.com/2024/05/23/gua… via STAT

$MRUS $IOVA $GMAB $IMCR $CADL $TGTX $VSTM
- ASCO 2024 abstract movers – Merus convinces, for now
oncologypipeline.com/apexonco/asco-…

$VSTM
- Verastem spoils its ASCO bounce oncologypipeline.com/apexonco/veras…

$MRUS
- ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody
pharmaceutical-technology.com/news/asco-2024… via Pharma Technology Focus

$MRUS
- Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting globenewswire.com/news-release/2…

$BMY $IOVA
- ASCO: Bristol Myers unveils I-O triplet data in melanoma as Iovance touts 'paradigm-changing' combo result fiercepharma.com/pharma/asco-br…

$RCUS $GILD
- ASCO24: Gilead, Arcus' etrumadenant extends survival in refractory colorectal cancer firstwordpharma.com/story/5860337 via FirstWord Pharma

$IMCR
- ASCO24: Immunocore tumbles as melanoma bispecific data fail to impress firstwordpharma.com/story/5860376 via FirstWord Pharma